Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan H Fox

Showing results (71-80 of 178) with videos related to

Pageof 18
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|January 17, 2018
Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson diseaseSean J Udow, Maria Eliza Freitas, Susan H Fox, et al.
Neurobiology of Aging|June 22, 2010
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPAPhilippe Huot, Tom H Johnston, Lieke Winkelmolen, et al.
Experimental Neurology|October 14, 2003
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's diseaseBrian Henry, Susan Duty, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 19, 2007
Ipratropium bromide spray as treatment for sialorrhea in Parkinson's diseaseTeri R Thomsen, Wendy R Galpern, Abena Asante, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2010
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's diseaseTom H Johnston, Anne van der Meij, Jonathan M Brotchie, et al.
Neuropharmacology|June 15, 2015
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 9, 2002
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystoniaSusan H Fox, Mark Kellett, A Peter Moore, et al.
Pharmacological Reviews|January 16, 2013
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Neuropharmacology|June 23, 2012
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Experimental Neurology|January 15, 2005
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's diseaseTom H Johnston, Joohyung Lee, Jordi Gomez-Ramirez, et al.
Pageof 18

Showing results (71-80 of 178) with videos related to

Sort By:
Pageof 18
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|January 17, 2018
Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson diseaseSean J Udow, Maria Eliza Freitas, Susan H Fox, et al.
Neurobiology of Aging|June 22, 2010
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPAPhilippe Huot, Tom H Johnston, Lieke Winkelmolen, et al.
Experimental Neurology|October 14, 2003
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's diseaseBrian Henry, Susan Duty, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 19, 2007
Ipratropium bromide spray as treatment for sialorrhea in Parkinson's diseaseTeri R Thomsen, Wendy R Galpern, Abena Asante, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2010
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's diseaseTom H Johnston, Anne van der Meij, Jonathan M Brotchie, et al.
Neuropharmacology|June 15, 2015
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 9, 2002
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystoniaSusan H Fox, Mark Kellett, A Peter Moore, et al.
Pharmacological Reviews|January 16, 2013
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Neuropharmacology|June 23, 2012
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Experimental Neurology|January 15, 2005
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's diseaseTom H Johnston, Joohyung Lee, Jordi Gomez-Ramirez, et al.
Pageof 18